Moneycontrol PRO
HomeNewsBusinessCompaniesFIPB clears 12 FDI proposals worth Rs 343 cr

FIPB clears 12 FDI proposals worth Rs 343 cr

The Government has cleared 12 FDI proposals worth Rs 343 crore and kept on hold the decision on US-based Mylan Inc's proposal to acquire an Indian pharma company.

August 06, 2013 / 21:24 IST

The Government has cleared 12 FDI proposals worth Rs 343 crore and kept on hold the decision on US-based Mylan Inc's proposal to acquire an Indian pharma company.


"Based on the recommendations of the foreign Investment Promotion Board (FIPB) in its meeting held on July 5, the government has approved 12 proposals of foreign direct investment amounting to Rs 343.39 crore," a statement said. However, the decision on Rs 5,168 crore proposal of Mylan Inc to acquire an Indian pharma company engaged in manufacture of generic pharma products was "kept in abeyance" till the formulation of the revised FDI policy by DIPP.

Also read: FDI into India rises 24% to $ 3.95 bn in April-May


The Department of Industrial Policy and Promotion (DIPP) is in the process of finalising its FDI policy on brown field pharma projects involving transfer of control. According to a 'Share Purchase Agreement', Mylan would acquire entire issued and outstanding share capital of Agila Specialities Pvt Ltd -- a subsidiary of pharma firm Strides Arcolab. Agila would be acquired by Mylan directly or through one of its subsidiaries.


The agreement was entered between Mylan, Strides Arcolab and its two promoter entities -- Arun Kumar and Pronomz Ventures LLP -- in February, this year. The proposals which were cleared by the FIPB include that of Sutures (I) Pvt Ltd to increase FDI holding in the company by another 26 per cent, from the current 35.28 per cent worth Rs 160 crore.


The other proposals which were approved include that of BNP Paribas, Total Prosthetics & Onthotics, Imperial Cancer Hospital and Research, and Life Positive Pvt Ltd. Besides, the board at its meeting deferred four proposals
and rejected three.


Also the proposal of Symbiotec Pharmalab worth Rs 330 crore for transfer of shares to a foreign company has been kept in abeyance pending DIPP policy on FDI in pharma. The FIPB also kept in abeyance 6 proposals, including that of Franklin Templeton Asset Management to set up an Alternative Investment Fund (AIF) in India.

first published: Aug 6, 2013 09:24 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347